INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institut
![Foto de INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA](/img/noimage.png)
![Foto de Ludwig Maximilian University of Munich](/img/noimage_org.png)
Ludwig Maximilian University of Munich
Múnich, AlemaniaPublicacions en col·laboració amb investigadors/es de Ludwig Maximilian University of Munich (63)
2024
-
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
HemaSphere, Vol. 8, Núm. 7
-
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
International Journal of Molecular Sciences, Vol. 24, Núm. 20
-
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717
-
Identifying Early Infections in the Setting of CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
HemaSphere, Vol. 7, Núm. 4, pp. E858
-
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
American Journal of Hematology, Vol. 98, Núm. 11, pp. 1699-1710
-
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020
-
Trends on Communication, Educational Assessment, Sustainable Development, Educational Innovation, Mechatronics and Learning Analytics at TEEM 2022
Lecture Notes in Educational Technology (Springer Science and Business Media Deutschland GmbH), pp. 699-716
2022
-
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 6, pp. 1855-1865
-
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
-
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6
-
Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1
-
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024
-
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1953-1963
-
Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1986-1998.e2
2021
-
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144
-
Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit
Schizophrenia Research, Vol. 227, pp. 10-17
-
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis
American Journal of Human Genetics, Vol. 108, Núm. 2, pp. 284-294